Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Authors
Keywords
-
Journal
IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-10-24
DOI
10.1111/imm.13141
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity
- (2019) James RM Black et al. Immunotherapy
- Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
- (2019) Douglas B. Johnson et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
- (2019) H. K. Akturk et al. DIABETIC MEDICINE
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
- (2018) Dipti M Karamchandani et al. JOURNAL OF CLINICAL PATHOLOGY
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
- (2018) Yoh Zen et al. MODERN PATHOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC
- (2018) Fernando Costa Santini et al. Cancer Immunology Research
- Identifying and managing the adverse effects of immune checkpoint blockade
- (2018) Arthur Winer et al. Journal of Thoracic Disease
- Enterocolitis due to immune checkpoint inhibitors: a systematic review
- (2018) Emilie Soularue et al. GUT
- Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors
- (2018) Karthik Suresh et al. Journal of Thoracic Oncology
- PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
- (2018) Lindsay J. Celada et al. Science Translational Medicine
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
- (2017) Ichiro Yamauchi et al. THYROID
- Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
- (2017) Alessandro Inno et al. TUMORI
- Sinusoid endotheliitis as a histological parameter for diagnosing acute liver allograft rejection
- (2017) Yu Shi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
- (2017) Frédéric Illouz et al. Cancer Medicine
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
- (2017) Sarah Chuzi et al. Cancer Management and Research
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
- (2017) Alessandro Inno et al. TUMORI JOURNAL
- In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis
- (2017) Han-Huei Lin et al. Scientific Reports
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
- (2016) M. Nishino et al. CLINICAL CANCER RESEARCH
- Immune-mediated respiratory adverse events of checkpoint inhibitors
- (2016) Samer Tabchi et al. CURRENT OPINION IN ONCOLOGY
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
- (2016) Edurne Arriola et al. Journal of Thoracic Oncology
- Anti-PD1-induced collagenous colitis in a melanoma patient
- (2016) Barouyr Baroudjian et al. MELANOMA RESEARCH
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Ipilimumab-associated Hepatitis
- (2015) Melanie Johncilla et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
- (2015) S. Kanameishi et al. ANNALS OF ONCOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Liver inflammation abrogates immunological tolerance induced by Kupffer cells
- (2015) Felix Heymann et al. HEPATOLOGY
- Meta-Analysis: The Relationship Between CTLA-4 +49 A/G Polymorphism and Primary Biliary Cirrhosis and Type I Autoimmune Hepatitis
- (2015) Ebrahim Eskandari-Nasab et al. IMMUNOLOGICAL INVESTIGATIONS
- Diagnosis of Primary Hypophysitis in Germany
- (2015) Jürgen Honegger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
- (2015) Matthew Howell et al. LUNG CANCER
- Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
- (2015) Jimmy Z Liu et al. NATURE GENETICS
- Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
- (2015) Mizuki Nishino et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
- (2015) Jennifer A. Lo et al. JAMA Oncology
- Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
- (2015) Antonio Grimaldi et al. Journal for ImmunoTherapy of Cancer
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
- (2014) Yanping Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
- (2014) Desirée Schubert et al. NATURE MEDICINE
- Identifying Gut Microbe-Host Phenotype Relationships Using Combinatorial Communities in Gnotobiotic Mice
- (2014) J. J. Faith et al. Science Translational Medicine
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Dysfunctional CD39POSregulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis
- (2013) Charlotte R. Grant et al. HEPATOLOGY
- Ipilimumab associated hepatitis: imaging and clinicopathologic findings
- (2013) Kyung Won Kim et al. INVESTIGATIONAL NEW DRUGS
- Ipilimumab-induced Perforating Colitis
- (2013) Kisha A. Mitchell et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Human Hepatic Stellate Cells Inhibit T-Cell Response Through B7-H1 Pathway
- (2013) Ronald Charles et al. TRANSPLANTATION
- Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
- (2012) Grégoire Berthod et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease
- (2012) F. Torino et al. ONCOLOGIST
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deficiency in B7-H1 (PD-L1)/PD-1 Coinhibition Triggers Pancreatic β-Cell Destruction by Insulin-Specific, Murine CD8 T-Cells
- (2010) Tarvo Rajasalu et al. DIABETES
- Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice
- (2009) Deepak Yadav et al. CELLULAR IMMUNOLOGY
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Naturally-existing CD4+CD25+Foxp3+ regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen
- (2009) Gerald P. Morris et al. JOURNAL OF AUTOIMMUNITY
- Fatal Autoimmune Hepatitis Induced by Concurrent Loss of Naturally Arising Regulatory T Cells and PD-1-Mediated Signaling
- (2008) Masahiro Kido et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started